Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival

Yi-Chen Lee, Yi-Hsin Yang, Jinu-Huang Su, Hsueh-Ling Chang, Ming-Feng Hou and Shyng-Shiou F. Yuan
Yi-Chen Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Hsin Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinu-Huang Su
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsueh-Ling Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Feng Hou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shyng-Shiou F. Yuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-11-0399 Published September 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, the expression of visfatin in breast cancer tissues. The expression of visfatin in breast cancer tissues, as determined by immunohistochemistry, was divided into 4 categories according to positive staining of tumor cells: score 1, 25% or less; score 2, 26% to 50%; score 3, 51% to 75%; and score 4, 76% or more. The expression of visfatin in the matched adjacent normal breast tissues/noncancerous tissues is also shown. B, representative immunohistochemistry images for the localization of visfatin, ER, PR, and Her2/neu in 2 cancer tissues (#1 and #2).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Kaplan–Meier survival curves generated for disease-free and overall survival according to 4 staining intensities of visfatin (A), low and high visfatin expression groups alone (B) or in combination with ER status (C) and PR status (D).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Kaplan–Meier survival curves for disease-free and overall survival for the low and high visfatin expression groups regarding the administration of adjuvant radiotherapy (A and B), chemotherapy (C and D), and hormone therapy (E and F).

Tables

  • Figures
  • Additional Files
  • Table 1.

    Correlation of visfatin expression with clinicopathologic characteristics of breast cancer patients

    VariablesItemVisfatinPa
    LowHigh
    n%n%
    StageI/II4756.63643.40.091
    III/IV836.41463.6
    GradeI/II4155.43344.60.338
    III1445.21754.8
    Age, y≤503257.12442.90.296
    502346.92653.1
    BMI, kg/m2<243149.23250.80.425
    ≥242457.11842.9
    Tumor size, cm<23164.61735.40.022
    ≥22442.13357.9
    LN metastasis0–14657.53442.50.060
    ≥2936.01664.0
    ERNegative1233.32466.70.005
    Positive4362.32637.7
    PRNegative1737.82862.20.009
    Positive3863.32236.7
    Her2/neuNegative3146.33653.70.096
    Positive2463.21436.8
    • aP value was calculated by the χ2 test.

  • Table 2.

    Correlation of visfatin expression with disease recurrence with/without radiotherapy, chemotherapy, or hormone therapy

     Low visfatin expressionPHigh visfatin expressionP
    RecurrenceRecurrence
    NoYesNoYes
    n%n%n%n%
    Radiotherapy
     No1885.7314.30.359a1568.2731.80.981b
     Yes3294.125.91967.9932.1
    Chemotherapy
     No12100.000.00.574a666.7333.30.100a
     Yes3888.4511.62868.31331.7
    Hormone therapy
     No10100.000.00.572a1551.71448.30.005a
     Yes4088.9511.11990.529.5
    • aThe P value was calculated by Fisher's exact test.

    • bThe P value was calculated by the χ2 test.

  • Table 3.

    Univariate and multivariate analyses of disease-free survival for breast cancer

    VariablesItemUnivariateMultivariate
    Hazard rate ratio95% CIPHazard rate ratio95% CIP
    StageIII/IV5.332.25–12.62<0.0016.081.83–20.180.003
    I/II1.001.00
    GradeIII1.380.55–3.420.4911.100.39–3.050.862
    I/II1.001.00
    Age, y504.271.56–11.660.0052.190.73–6.560.163
    ≤501.001.00
    BMI, kg/m2<241.790.76–4.220.1831.540.59–4.040.377
    ≥241.001.00
    ERNegative2.451.04–5.770.0410.690.12–3.940.674
    Positive1.001.00
    PRNegative1.990.84–4.720.1203.760.74–19.150.111
    Positive1.001.00
    Her2/neuPositive0.700.27–1.800.4550.640.22–1.870.413
    Negative1.001.00
    RadiotherapyYes0.690.29–1.620.3931.030.37–2.920.951
    No1.001.00
    ChemotherapyYes1.450.43–4.910.5550.880.23–3.410.848
    No1.001.00
    Hormone therapyYes0.180.07–0.47<0.0010.440.11–1.760.247
    No1.001.00
    VisfatinHigh5.731.92–17.140.0024.111.15–14.700.030
    Low1.001.00
  • Table 4.

    Univariate and multivariate analyses of overall survival for breast cancer

    VariablesItemUnivariateMultivariate
    Hazard rate ratio95% CIPHazard rate ratio95% CIP
    StageIII/IV5.001.81–18.830.00210.172.41–42.940.002
    I/II1.001.00
    GradeIII1.850.65–5.230.2471.290.38–4.380.686
    I/II1.001.00
    Age, y508.221.85–36.430.0064.110.86–19.530.076
    ≤501.001.00
    BMI, kg/m2<242.310.82–6.490.1133.550.98–12.840.054
    ≥241.001.00
    ERNegative4.341.48–12.700.0072.130.18–25.150.549
    Positive1.001.00
    PRNegative3.971.26–12.460.0187.100.71–70.590.095
    Positive1.001.00
    Her2/neuPositive1.140.40–3.200.8081.050.29–3.840.940
    Negative1.001.00
    RadiotherapyYes0.520.19–1.430.2050.430.11–1.650.220
    No1.001.00
    ChemotherapyYes1.510.34–6.720.5850.450.08–2.560.364
    No1.001.00
    Hormone TherapyYes0.180.06–0.570.0031.570.26–9.580.627
    No1.001.00
    VisfatinHigh5.051.42–17.980.0126.201.18–32.500.031
    Low1.001.00

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Table 1 - PDF file - 109K
    • Supplementary Table 2 - PDF file - 44K
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 20 (9)
September 2011
Volume 20, Issue 9
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival
Yi-Chen Lee, Yi-Hsin Yang, Jinu-Huang Su, Hsueh-Ling Chang, Ming-Feng Hou and Shyng-Shiou F. Yuan
Cancer Epidemiol Biomarkers Prev September 1 2011 (20) (9) 1892-1901; DOI: 10.1158/1055-9965.EPI-11-0399

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival
Yi-Chen Lee, Yi-Hsin Yang, Jinu-Huang Su, Hsueh-Ling Chang, Ming-Feng Hou and Shyng-Shiou F. Yuan
Cancer Epidemiol Biomarkers Prev September 1 2011 (20) (9) 1892-1901; DOI: 10.1158/1055-9965.EPI-11-0399
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Life Risk Factors for Breast Cancer
  • Sugary Drink Consumption and Colorectal Cancer Risk
  • HPV Testing in Self-samples and Urine
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement